Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients

Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients

The therapeutic goal for hepatitis B virus (HBV) infection is HBs antigen (HBsAg) seroclearance, which is achieved through 48-week pegylated interferon (Peg-IFN) therapy. This study aimed to identify predictive biomarkers for sustained HBsAg reduction by analyzing serum microRNAs. Twenty-two consecu...

Full description

Bibliographic Details
Main Authors: Koji Fujita, Shima Mimura, Hisakazu Iwama, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Takako Nomura, Joji Tani, Hirohito Yoneyama, Asahiro Morishita, Makoto Oryu, Takashi Himoto, Hironori Nishitsuji, Kunitada Shimotohno, Masao Omata, Tsutomu Masaki
Format: Article
Language:English
Published: MDPI AG 2018-07-01
Series:International Journal of Molecular Sciences
Subjects:
hepatitis B surface antigens
hepatitis B virus
interferons
microRNAs
solute carrier proteins
Online Access:http://www.mdpi.com/1422-0067/19/7/1940

Internet

http://www.mdpi.com/1422-0067/19/7/1940

Similar Items